Zepbound and Wegovy are the two GLP-1 brands that share a chronic weight-management indication, which makes them the most direct comparison in the class. This independent review weighs semaglutide against tirzepatide on mechanism, labels, SURPASS-2 evidence, side effects, and cost, plus the genetic groundwork beneath either regimen.

This overview compares Zepbound and Ozempic through the lens of their FDA labels first, since regulatory scope drives prescribing and coverage. As of April 2026 it works through indications, dual-versus-single molecule design, trial findings, tolerability, pricing, and the shared genetic terrain.

This overview places Zepbound and Mounjaro within the broader incretin-therapy landscape rather than as an isolated pair. Both are tirzepatide from Eli Lilly; as of April 2026 it maps them against the full GLP-1 field by indication, trial structure, safety, access, and shared genetics.

Zepbound cost depends on more than a single number. This overview covers the published April 2026 list price, how insurance and prior authorization change the math, manufacturer and pharmacy savings, compounded alternatives, and the genetic pathway context behind these metabolic decisions.

Zepbound is the first medication cleared specifically for obstructive sleep apnea in adults with obesity. This overview explains the indirect airway mechanism through weight reduction, what the SURMOUNT-OSA trial measured, the safety profile to weigh, and the genetic pathways that shape appetite, satiety, and energy balance.

The number to separate is Zepbound's roughly $1,059 monthly list price versus what you actually pay after everything else runs its course. This overview walks the staircase between them, insurance, indication, savings cards, and compounded pathways, and adds the genetic context PlexusDx places upstream of any protocol decision.

Zepbound is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist approved for chronic weight management and sleep apnea in adults with obesity. This overview covers its dual-incretin mechanism, what the class treats, side effects, the April 2026 cost landscape, and how genetics relate to GLP-1 pathways.

Wegovy is Novo Nordisk's brand of semaglutide, a GLP-1 receptor agonist approved for chronic weight management. This overview separates the brand from the molecule, covering how the pathway works, what the class treats, side effects, the April 2026 cost landscape, and how genetics relate to GLP-1 pathways.

Tirzepatide is a GIP/GLP-1 dual agonist and the active ingredient behind more than one brand, notable for engaging a second incretin receptor. This overview covers how it works, what the class treats, its side effects, the April 2026 cost landscape, and how genetics relate to GLP-1 pathways.

Semaglutide is a GLP-1 receptor agonist and the shared active ingredient behind several branded products. This overview explains how the pathway works, what the class treats, its side-effect profile, the April 2026 cost landscape, and how genetics relate to GLP-1 pathways.

Retatrutide is an investigational once-weekly triple hormone receptor agonist in development, not FDA-approved and not commercially available. This overview explains what it is, how it is designed to work, the conditions being studied, safety context, and why genetics still matters.

Ozempic is Novo Nordisk's brand of semaglutide, a GLP-1 receptor agonist engineered to resist DPP-4 breakdown for sustained receptor engagement. This overview covers how it works, its FDA-approved uses, side effects, the April 2026 cost landscape, and how genetics relate to GLP-1 pathways.

Mounjaro is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist whose two-incretin mechanism sets it apart from single-receptor GLP-1 drugs. This overview covers its mechanism, FDA-approved uses, side effects, the April 2026 cost landscape, and how genetics relate to GLP-1 pathways.

Wegovy and Zepbound are the two FDA-approved weight-management brands, but they run on different molecules. This editorial comparison examines what each label covers, the trial programs behind them, how tolerability stacks up, and the genetic architecture both compounds ultimately act on.

Wegovy and Ozempic are the same molecule wearing two labels. This editorial comparison explains how dose ceiling and FDA indication set them apart, what the evidence and cost picture look like, and why your semaglutide biology starts at the genetic level long before a prescription.

Every Wegovy price you see quoted online reflects a different set of variables. This guide breaks down the five factors behind the number, how coverage and Medicare decide what you pay, what compounding changed across 2024 and 2025, and three realistic out-of-pocket scenarios.

This overview places Wegovy in the wider GLP-1 landscape: one molecule sold under several brand names, a shared class mechanism, the trial programs clinicians consult, the cautions built into the drug class, and the genetic terrain that shapes every metabolic decision.

How much Wegovy costs depends entirely on your situation. This scenario-first guide starts from the published list price, then walks through what covered, partially-covered, and uninsured patients each tend to face, plus the separately priced compounded pathway, all as of April 2026.

How is Trulicity considered clinically for weight management? This overview frames dulaglutide within the wider GLP-1 class, summarizes the mechanism and the trial programs clinicians reference, outlines the class safety profile, and explains the inherited pathway biology that precedes any compound decision.

A full overview comparing tirzepatide and semaglutide: their differing receptor blueprints, the FDA approvals that shape each prescription, the trial evidence read program by program, the safety picture, cost of access, and the shared genetic groundwork that applies whichever compound a provider prescribes.

This overview looks at how tirzepatide works inside the body for weight management, acting on appetite, satiety, and gastric emptying rather than willpower. It covers the evidence to consult, the contraindications worth knowing, and the genetic variables upstream of any decision.

The real cost of tirzepatide is the gap between its list price and what you pay after coverage. This guide traces the drivers, prior-authorization mechanics, savings-card caps, and compounded pathways, then explains the genetic context that should frame any protocol decision before you spend.

This overview maps semaglutide and tirzepatide within the wider GLP-1 family, covering receptor design, the FDA approval timeline, major trial programs, class-wide safety, the list-price band, and the FTO, GLP1R, MC4R, and TCF7L2 variants common to every molecule in the category.

This companion overview goes past the basics of semaglutide for weight management, covering how dosing is titrated, which trial programs to consult, the class safety profile, and the specific gene variants that describe metabolic terrain. It stays tied to labeling and published evidence throughout.

Searching the semaglutide 2 mg dose usually means you are at or near that titration step. This page explains where the step fits in a labeled schedule, what patients commonly report, which symptoms deserve a call to a provider, and the inherited biology that sits beneath every dose decision.

Rybelsus and weight loss is a frequent search, though the picture involves mechanism, regulatory status, and evidence. This guide covers what the oral semaglutide brand is, how GLP-1 signaling relates to weight, which trials to consult, the safety profile, and the genetic variables underneath.

Rybelsus is the oral semaglutide brand FDA-approved for type 2 diabetes. This guide frames what the label establishes about titration structure, tolerability during dose steps, and the monitoring that applies, while carefully leaving all specific dosing and titration direction to your prescribing provider.

Tirzepatide and Retatrutide are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

This independent overview frames Ozempic versus Wegovy as a set of decision layers, from active ingredient and indication to evidence, safety, cost, and genetics, showing why the shared semaglutide molecule makes labeled indication and genetic context the inputs that matter most in the comparison.

This independent overview maps the incretin category that surrounds Ozempic and Mounjaro, covering GLP-1-selective, dual, and investigational agents, FDA approval timelines, the major trial programs, class-wide safety, the list-price spread, and the shared genetics behind every compound in the family.